ArticleNature communications2024
TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Article
- TRIM7 Inhibits Rabies Virus Replication by Promoting K48-Linked Ubiquitination and Degradation of RABV-M.Emerging microbes & infections · 2026Article
- Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Comparative progress on the mechanisms of airway mucosal injury induced by different pathogens: SARS-CoV-2, influenza A virus, and Mycoplasma pneumoniae.Frontiers in cellular and infection microbiology · 2026Review
- C-terminus-outward orientation of SARS-CoV-2 envelope proteins on viral capsid enables a novel virus-cell interaction pathway.Frontiers in cellular and infection microbiology · 2026Article
- Rewriting the viral script: post-translational modifications orchestrating SARS-CoV-2 pathogenesis and immune evasion.Frontiers in microbiology · 2026Review
- Genome-Wide DNA Methylation and RNA Analysis Reveal Epigenetic and Transcriptomic Changes in Carbapenem-Resistant Klebsiella pneumoniae Strains.Current microbiology · 2025Article
- Post-Translational Modifications in Respiratory Virus Infection: Recent Insights into the Development of In Vitro Models.International journal of molecular sciences · 2025Review
- Mammalian innate antiviral defenses: beyond interferon.Journal of virology · 2025Review
- TRIM7 suppresses transmissible gastroenteritis virus replication by targeting the degradation of N protein and activating RIG-I-mediated type I IFN antiviral response.Veterinary research · 2025Article
- IL-4 and TGF-β regulate inflammatory cytokines and cellular infiltration in the lung and systemic IL-6 in mouse-adapted SARS-CoV-2 infection.ImmunoHorizons · 2025Article
- A No-Brainer! The Therapeutic Potential of TRIM Proteins in Viral and Central Nervous System Diseases.Viruses · 2025Review
- DHCLHAM: microbe-drug interaction prediction based on dual-hypergraph contrastive learning framework with hierarchical attention mechanism.Frontiers in microbiology · 2025Article
- The Dual Role of TRIM7 in Viral Infections.Viruses · 2024Review
- Review
Corrections and comments
- Update of
Authors and funding
28 authors.
Maria Gonzalez-OrozcoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Hsiang-Chi TsengCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ, USA.ORCID 0000-0001-7745-413X
Adam HageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0001-7668-892X
Hongjie XiaDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-2520-7038
Padmanava BeheraCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Kazi AfreenCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Yoatzin Peñaflor-TellezCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Maria I GiraldoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Matthew HuanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Lucinda Puebla-ClarkDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
Sarah van TolDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-9905-920X
Abby OdleCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Matthew CrownHub for Biotechnology in the Built Environment, Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle, UK.
Natalia TeruelDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Thomas R SheliteDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
Joaquin Moreno-ContrerasCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Kaori TerasakiDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Shinji MakinoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-7831-1576
Vineet MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0001-8803-7606
Mark EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Janice J EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-3883-8250
Rafael J NajmanovichDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-6971-7224
Matthew BashtonHub for Biotechnology in the Built Environment, Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle, UK.ORCID 0000-0002-6847-1525
Robin StephensDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0001-5553-1616
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0003-0918-016X
Alexander N FreibergDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0001-8413-8960
Ricardo RajsbaumDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. ricardo.rajsbaum@rutgers.edu.ORCID 0000-0002-5058-5444
Funding
Research Project 3: Role of Posttranslational Protein Modifications in the Pathogenesis of Ebola Virus DiseaseP01AI150585 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER · 2021 to 2025
$11.3MUTMB WOMEN'S HEALTH RESEARCH SCHOLARS PROGRAMK12HD052023 · NICHD · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI BERENSON, ABBEY B · 2005 to 2023
$8.1MRegulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1MThe Role of the Host Ubiquitin System in Promoting SARS-CoV-2 Replication and PathogenesisR01AI166668 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2021 to 2025
$2.6MThe Role of TRIM6 and Ubiquitin in Influenza Virus-Induced PathologyR01AI155466 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Ricardo Rajsbaum · 2021 to 2026
$2.5MThe Germinal Center and T cell help in Three Phases of Clearance of PlasmodiumR01AI135061 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI STEPHENS, ROBIN · 2018 to 2022
$2.0MInterplay between coronaviruses and nonsense-mediated mRNA decay pathwayR01AI146081 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MAKINO, SHINJI · 2020 to 2023
$1.2MDivision of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) P01AI150585Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI155466NIAID NIH HHS P01 AI150585NIAID NIH HHS R01 AI134907NIAID NIH HHS R01 AI135061NIAID NIH HHS R01 AI146081NIAID NIH HHS R01 AI155466NIAID NIH HHS R01 AI166668NICHD NIH HHS K12 HD052023
Abstract
SARS-CoV-2 is a highly transmissible virus that causes COVID-19 disease. Mechanisms of viral pathogenesis include excessive inflammation and viral-induced cell death, resulting in tissue damage. Here we show that the host E3-ubiquitin ligase TRIM7 acts as an inhibitor of apoptosis and SARS-CoV-2 replication via ubiquitination of the viral membrane (M) protein. Trim7
Indexed as
ApoptosisCOVID-19Mice, KnockoutSARS-CoV-2Tripartite Motif ProteinsUbiquitinationUbiquitin-Protein LigasesVirus ReplicationAnimalsCoronavirus M ProteinsFemaleHEK293 CellsHumansMiceMice, Inbred C57BLMutationCoronavirus M Proteinsmembrane protein, SARS-CoV-2TRIM7 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.